Avanos Medical, Inc. (NYSE:AVNS) Q1 2024 Earnings Call Transcript

Operator: Thank you. There are no further questions. You may proceed with closing comments.

Joe Woody: Good. Our focus has been on execution. We have done a lot of things, successfully executing on the product exits, divesting RH, making the Diros acquisition and increasing our shareholdings through our repurchase program. I think we’ve established now the foundation to meet our midterm financial commitments, our transformation priorities and shaping our portfolio which we think are in an attractive market. So we’re confident that we’re well positioned, as we outlined in the script, for sales growth, margin expansion and meaningful free cash flow generation through ’24 and accelerating that in ’25. So I appreciate everyone’s attendance on the call. Thank you and your continued following of Avanos.

Operator: Ladies and gentlemen, this concludes your conference for today. We thank you for participating and we ask that you please disconnect your lines.